Pharmaceuticals

Molecular Targeted Therapy Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the molecular targeted therapy market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Molecular Targeted Therapy Market be in 2030 compared with 2026?

The molecular targeted therapy market has experienced robust growth in recent years. It is forecast to expand from $71.64 billion in 2025 to $77.89 billion in 2026, at a compound annual growth rate (CAGR) of 8.7%. The market’s historical growth can be attributed to developments in cancer genomics research, the advancement of monoclonal antibodies, numerous oncology drug approvals, the establishment of hospital oncology centers, and expanded clinical trials.

The molecular targeted therapy market size is poised for substantial growth over the next few years. By 2030, its value is estimated to reach $107.64 billion, progressing at a compound annual growth rate (CAGR) of 8.4%. This expansion is primarily driven by the increase in personalized cancer treatment, wider adoption of next-generation sequencing, AI-driven drug discovery initiatives, the global burden of oncology, and improved reimbursement for targeted therapies. Key developments anticipated during this period include the broadening of precision oncology, greater utilization of biomarker-based therapies, an expanding pipeline of targeted cancer drugs, the integration of companion diagnostics, and a rise in the application of combination targeted therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

What Drivers Are Guiding Growth Patterns In The Molecular Targeted Therapy Market?

The growth of the molecular targeted therapy market is expected to be propelled by the rising trend of personalized medicine. This healthcare approach customizes treatment and prevention based on an individual’s genetic profile, lifestyle, and environmental factors. Personalized medicine is gaining prominence due to the increasing availability of genetic data, which enables treatments to be tailored to individual genomes for enhanced efficacy and reduced side effects. It supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, facilitating the selection of therapies that directly target those abnormalities. This method improves treatment precision and minimizes harm to healthy tissues. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 approvals in 2022. Therefore, the rise of personalized medicine is significantly driving the growth of the molecular targeted therapy market.

Which Segments Are Driving Activity In The Molecular Targeted Therapy Market?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Molecular Targeted Therapy Market?

Major companies active within the molecular targeted therapy market are prioritizing the development of advanced products, including small molecule inhibitors, to improve patient outcomes in various cancers and chronic diseases. Small molecule inhibitors are minute compounds that can easily penetrate cells and inhibit specific proteins driving disease progression. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is designed for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved test. This approval is founded on the Phase 3 CodeBreaK 300 trial, which revealed that the combination more than doubled progression-free survival compared to the investigated standard of care, establishing it as the first targeted therapy to demonstrate such a benefit in this chemorefractory patient population.

Which Key Market Players Are Investing In Expansion And Innovation Within The Molecular Targeted Therapy Market?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Which Regions Are Poised For Strategic Growth In The Molecular Targeted Therapy Market?

North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Molecular Targeted Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp

Browse Through More Reports Similar to the Global Molecular Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795